Links for fulltext
     (May Require Subscription)
Supplementary

Article: Non-gastric marginal zone B cell lymphoma: Clinicopathologic features and treatment results

TitleNon-gastric marginal zone B cell lymphoma: Clinicopathologic features and treatment results
Authors
KeywordsFludarabine
Mucosa-associated lymphoid tissue
Non-gastric marginal zone lymphoma
Rituximab
Splenic marginal zone lymphoma
Issue Date2011
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htm
Citation
Annals Of Hematology, 2011, v. 90 n. 12, p. 1399-1407 How to Cite?
AbstractThe optimal treatment strategy and outcome of non-gastric marginal zone lymphoma (MZL) remains undefined. The role of rituximab and fludarabine in MZL has not been critically appraised and compared with conventional chemotherapy. We retrospectively analyzed 81 consecutive patients with non-gastric MZL (mucosa-associated lymphoid tissue lymphoma, n = 66; splenic MZL, n = 11; nodal MZL, n = 4). As a group, the treatment results were favorable, with an overall response rate of 87% and a complete response (CR) rate of 73%. The CR rate was similar for conventional chemotherapy, and rituximab- and fludarabine-containing regimens. However, the relapse rate was significantly decreased in rituximab- and fludarabine-containing regimens. The use of rituximab and fludarabine was associated with acceptable side effects. For splenic MZL, splenectomy was significantly associated with a superior CR rate. Early stage, good performance status, and low international prognostic index risk scores significantly impacted on CR rate and survivals. Rituximab and fludarabine were safe for non-gastric MZL and resulted in more durable remissions. © 2011 The Author(s).
Persistent Identifierhttp://hdl.handle.net/10722/137368
ISSN
2015 Impact Factor: 3.022
2015 SCImago Journal Rankings: 1.117
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorGill, Hen_HK
dc.contributor.authorChim, CSen_HK
dc.contributor.authorAu, WYen_HK
dc.contributor.authorLoong, Fen_HK
dc.contributor.authorTse, Een_HK
dc.contributor.authorLeung, AYHen_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2011-08-26T14:23:59Z-
dc.date.available2011-08-26T14:23:59Z-
dc.date.issued2011en_HK
dc.identifier.citationAnnals Of Hematology, 2011, v. 90 n. 12, p. 1399-1407en_HK
dc.identifier.issn0939-5555en_HK
dc.identifier.urihttp://hdl.handle.net/10722/137368-
dc.description.abstractThe optimal treatment strategy and outcome of non-gastric marginal zone lymphoma (MZL) remains undefined. The role of rituximab and fludarabine in MZL has not been critically appraised and compared with conventional chemotherapy. We retrospectively analyzed 81 consecutive patients with non-gastric MZL (mucosa-associated lymphoid tissue lymphoma, n = 66; splenic MZL, n = 11; nodal MZL, n = 4). As a group, the treatment results were favorable, with an overall response rate of 87% and a complete response (CR) rate of 73%. The CR rate was similar for conventional chemotherapy, and rituximab- and fludarabine-containing regimens. However, the relapse rate was significantly decreased in rituximab- and fludarabine-containing regimens. The use of rituximab and fludarabine was associated with acceptable side effects. For splenic MZL, splenectomy was significantly associated with a superior CR rate. Early stage, good performance status, and low international prognostic index risk scores significantly impacted on CR rate and survivals. Rituximab and fludarabine were safe for non-gastric MZL and resulted in more durable remissions. © 2011 The Author(s).en_HK
dc.languageengen_US
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htmen_HK
dc.relation.ispartofAnnals of Hematologyen_HK
dc.rightsThe Author(s)en_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong Licenseen_US
dc.subjectFludarabineen_HK
dc.subjectMucosa-associated lymphoid tissueen_HK
dc.subjectNon-gastric marginal zone lymphomaen_HK
dc.subjectRituximaben_HK
dc.subjectSplenic marginal zone lymphomaen_HK
dc.titleNon-gastric marginal zone B cell lymphoma: Clinicopathologic features and treatment resultsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0939-5555&volume=90&issue=12&spage=1399&epage=1407&date=2011&atitle=Non-gastric+marginal+zone+B+cell+lymphoma:+clinicopathologic+features+and+treatment+results-
dc.identifier.emailChim, CS:jcschim@hku.hken_HK
dc.identifier.emailTse, E:ewctse@hku.hken_HK
dc.identifier.emailLeung, AYH:ayhleung@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityChim, CS=rp00408en_HK
dc.identifier.authorityTse, E=rp00471en_HK
dc.identifier.authorityLeung, AYH=rp00265en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturepublished_or_final_versionen_US
dc.identifier.doi10.1007/s00277-011-1226-zen_HK
dc.identifier.pmid21476016-
dc.identifier.pmcidPMC3210355-
dc.identifier.scopuseid_2-s2.0-84355162301en_HK
dc.identifier.hkuros189630en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84355162301&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume90en_HK
dc.identifier.issue12en_HK
dc.identifier.spage1399en_HK
dc.identifier.epage1407en_HK
dc.identifier.eissn1432-0584en_US
dc.identifier.isiWOS:000296730700004-
dc.publisher.placeGermanyen_HK
dc.description.otherSpringer Open Choice, 21 Feb 2012en_US
dc.identifier.scopusauthoridGill, H=36086184900en_HK
dc.identifier.scopusauthoridChim, CS=7004597253en_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridLoong, F=6602794154en_HK
dc.identifier.scopusauthoridTse, E=7005019454en_HK
dc.identifier.scopusauthoridLeung, AYH=7403012668en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.citeulike9128568-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats